BriaCell Therapeutics Corp.

Toronto Stock Exchange BCT.TO

BriaCell Therapeutics Corp. Price to Earnings Ratio (P/E) on February 05, 2025: -0.66

BriaCell Therapeutics Corp. Price to Earnings Ratio (P/E) is -0.66 on February 05, 2025, a 89.29% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.

BriaCell Therapeutics Corp. 52-week high Price to Earnings Ratio (P/E) is -0.05 on January 20, 2025, which is 91.67% above the current Price to Earnings Ratio (P/E).
BriaCell Therapeutics Corp. 52-week low Price to Earnings Ratio (P/E) is -6.51 on February 06, 2024, which is -890.08% below the current Price to Earnings Ratio (P/E).
BriaCell Therapeutics Corp. average Price to Earnings Ratio (P/E) for the last 52 weeks is -2.34.

Key data

Date	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield

Toronto Stock Exchange: BCT.TO

BriaCell Therapeutics Corp.

CEO	Dr. William V. Williams M.D.
IPO Date	Aug. 13, 2012
Location	Canada
Headquarters	Bellevue Centre
Employees	16
Sector	Healthcare
Industries Biotechnology Clinical Trials Vaccines

Description

BriaCell Therapeutics Corp., an immuno-oncology-focused biotechnology company, engages in developing immunotherapies for the management of cancer. Its lead drug candidate is Bria-IMT, a whole-cell cancer vaccine that is in Phase I/IIa clinical trials in combination with the immunotherapy development candidates retifanlimab. The company is also developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test that determines the patients' HLA types. It has a non-exclusive clinical trial collaboration with Incyte Corporation to evaluate the effects of combinations of novel clinical candidates; and a cooperative research and development agreement with the National Cancer Institute to conduct preclinical studies to develop and test Bria-OTS cellular immunotherapy as a treatment for cancer. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.

Key trends

Past 5 years